Gyre Therapeutics reports 2023 revenue $113.5M, net loss $85.5M; ETUARY sales up 13%

GYRE THERAPEUTICS, INC.

Full year 2023 revenue of $113.5M, up from $102.3M in 2022; net loss of $85.5M vs net income of $4.3M in 2022.
ETUARY sales reached $112.1M in 2023, a 13% increase; sales team covers 35,512 hospitals across PRC.
Cash and cash equivalents $33.5M as of Dec 31, 2023 vs $25.2M end of 2022.
Phase 3 trial for F351 in CHB-associated liver fibrosis topline data expected by early 2025; U.S. Phase 2a in NASH planned for 2025.
Appointed Han Ying as CEO in January 2024; completed business combination with GNI in October 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GYRE THERAPEUTICS, INC. reported year ended December 31, 2023 results: revenue $112.1 million.

Period: year ended December 31, 2023
Revenue: $112.1 million
Result: reported results

Exact text from the filing

inflammation modulators. ETUARY became commercially available in the PRC in 2011 and has been included in the National Reimbursement Drug List since 2017. • Generated sales of $112.1 million in 2023. For the year ended December 31, 2023, Gyre Pharmaceuticals generated $112.1 million in sales of ETUARY, representing an increase of 13% from the previous year. As of

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-036135

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.